TY - JOUR
T1 - Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease
T2 - International MOGAD Panel proposed criteria
AU - Banwell, Brenda
AU - Bennett, Jeffrey L.
AU - Marignier, Romain
AU - Kim, Ho Jin
AU - Brilot, Fabienne
AU - Flanagan, Eoin P.
AU - Ramanathan, Sudarshini
AU - Waters, Patrick
AU - Tenembaum, Silvia
AU - Graves, Jennifer S.
AU - Chitnis, Tanuja
AU - Brandt, Alexander U.
AU - Hemingway, Cheryl
AU - Neuteboom, Rinze
AU - Pandit, Lekha
AU - Reindl, Markus
AU - Saiz, Albert
AU - Sato, Douglas Kazutoshi
AU - Rostasy, Kevin
AU - Paul, Friedemann
AU - Pittock, Sean J.
AU - Fujihara, Kazuo
AU - Palace, Jacqueline
N1 - Publisher Copyright:
© 2023 Elsevier Ltd
PY - 2023/3
Y1 - 2023/3
N2 - Serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG) are found in patients with acquired CNS demyelinating syndromes that are distinct from multiple sclerosis and aquaporin-4-seropositive neuromyelitis optica spectrum disorder. Based on an extensive literature review and a structured consensus process, we propose diagnostic criteria for MOG antibody-associated disease (MOGAD) in which the presence of MOG-IgG is a core criterion. According to our proposed criteria, MOGAD is typically associated with acute disseminated encephalomyelitis, optic neuritis, or transverse myelitis, and is less commonly associated with cerebral cortical encephalitis, brainstem presentations, or cerebellar presentations. MOGAD can present as either a monophasic or relapsing disease course, and MOG-IgG cell-based assays are important for diagnostic accuracy. Diagnoses such as multiple sclerosis need to be excluded, but not all patients with multiple sclerosis should undergo screening for MOG-IgG. These proposed diagnostic criteria require validation but have the potential to improve identification of individuals with MOGAD, which is essential to define long-term clinical outcomes, refine inclusion criteria for clinical trials, and identify predictors of a relapsing versus a monophasic disease course.
AB - Serum antibodies directed against myelin oligodendrocyte glycoprotein (MOG) are found in patients with acquired CNS demyelinating syndromes that are distinct from multiple sclerosis and aquaporin-4-seropositive neuromyelitis optica spectrum disorder. Based on an extensive literature review and a structured consensus process, we propose diagnostic criteria for MOG antibody-associated disease (MOGAD) in which the presence of MOG-IgG is a core criterion. According to our proposed criteria, MOGAD is typically associated with acute disseminated encephalomyelitis, optic neuritis, or transverse myelitis, and is less commonly associated with cerebral cortical encephalitis, brainstem presentations, or cerebellar presentations. MOGAD can present as either a monophasic or relapsing disease course, and MOG-IgG cell-based assays are important for diagnostic accuracy. Diagnoses such as multiple sclerosis need to be excluded, but not all patients with multiple sclerosis should undergo screening for MOG-IgG. These proposed diagnostic criteria require validation but have the potential to improve identification of individuals with MOGAD, which is essential to define long-term clinical outcomes, refine inclusion criteria for clinical trials, and identify predictors of a relapsing versus a monophasic disease course.
UR - http://www.scopus.com/inward/record.url?scp=85148034716&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(22)00431-8
DO - 10.1016/S1474-4422(22)00431-8
M3 - Review article
C2 - 36706773
AN - SCOPUS:85148034716
SN - 1474-4422
VL - 22
SP - 268
EP - 282
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 3
ER -